visitante ::
identificación
|
|||||||||||||||
Buscar | Enviar | Ayuda | Servicio de Bibliotecas | Sobre el DDD | Català English Español |
Página principal > Artículos > Artículos publicados > NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients |
Fecha: | 2017 |
Resumen: | Intermediate-risk acute myeloid leukemia (IR-AML) is the largest subgroup of AML patients and is highly heterogeneous. Whereas adverse and favourable risk patients have well-established treatment protocols, IR-AML patients have not. It is, therefore, crucial to find novel factors that stratify this subgroup to implement risk-adapted strategies. The CAS (Crk-associated substrate) adaptor protein family regulates cell proliferation, survival, migration and adhesion. Despite its association with metastatic dissemination and prognosis of different solid tumors, the role of these proteins in hematological malignancies has been scarcely evaluated. Nevertheless, previous work has established an important role for the CAS family members NEDD9 or BCAR1 in the migratory and dissemination capacities of myeloid cells. On this basis, we hypothesized that NEDD9 or BCAR1 expression levels could associate with survival in IR-AML patients and become new prognostic markers. To that purpose, we assessed BCAR1 and NEDD9 gene expression in a cohort of 73 adult AML patients validating the results in an independent cohort (n = 206). We have identified NEDD9, but not BCAR1, as a new a marker for longer overall and disease-free survival, and for lower cumulative incidence of relapse. In summary, NEDD9 gene expression is an independent prognostic factor for favourable prognosis in IR-AML patients. |
Ayudas: | Instituto de Salud Carlos III CD13-00074 Instituto de Salud Carlos III PI15-00378 Instituto de Salud Carlos III FIS PI11-00872 Instituto de Salud Carlos III RD12-0036-0071 Instituto de Salud Carlos III FIS PI14-00450 Instituto de Salud Carlos III PIE15-00028 Instituto de Salud Carlos III RD12-0036-0069 Instituto de Salud Carlos III RD12-0036-0014 Instituto de Salud Carlos III PS13-1640 Instituto de Salud Carlos III CIBER-BBN/CBV6-01-1031 Agència de Gestió d'Ajuts Universitaris i de Recerca 2014/SGR-1041 Agència de Gestió d'Ajuts Universitaris i de Recerca 2014/SGR-1281 Agència de Gestió d'Ajuts Universitaris i de Recerca 2014/PROD0005 |
Nota: | Altres ajuts: Fundació La Marató TV3 [416/C/2013-2030,100830/31/32]; Josep Carreras Leukemia Research Institute [P/AG 2014]; Spanish Health Research Program [PI12/02321]; Spanish Association Against Cancer (AECC) [to MCC]; and a grant from the Cellex Foundation, Barcelona. |
Nota: | Altres ajuts: PERIS/SLT002-16-00433 |
Derechos: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
Lengua: | Anglès |
Documento: | Article ; recerca ; Versió publicada |
Materia: | Acute myeloid leukemia ; Nedd9 ; Bcar1 ; Prognostic factor ; Intermediate-risk |
Publicado en: | Oncotarget, Vol. 8 (june 2017) , p. 76003-76014, ISSN 1949-2553 |
12 p, 10.4 MB |